EMA: new guidance for pharma on early HTA dialogue

EMA: new guidance for pharma on early HTA dialogue

The European Medicines Agency (EMA) has published draft best-practice guidance for industry on parallel scientific advice with health technology assessment (HTA) agencies, aimed at facilitating early dialogue between regulators, HTA bodies and drug developers.

Advertisement

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s